Evidence map›Paper›PMID 35648193›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2022

Sesamol protects against liver fibrosis induced in rats by modulating lysophosphatidic acid receptor expression and TGF-β/Smad3 signaling pathway.

Nesma A Abd Elrazik, Mohamed El-Mesery, Mamdouh M El-Shishtawy

Open access · hybridAbstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Sesamol as a potent anticancer compound: from chemistry to cellular interactions.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  9. Article
  10. RUNX1 promotes liver fibrosis progression through regulating TGF-β signalling.International journal of experimental pathology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nesma A Abd ElrazikDepartment of Biochemistry, Faculty of Pharmacy, Mansoura University, P.O. Box, Mansoura, 35516, Egypt.ORCID http://orcid.org/0000-0001-6354-1152
Mohamed El-MeseryDepartment of Biochemistry, Faculty of Pharmacy, Mansoura University, P.O. Box, Mansoura, 35516, Egypt.ORCID http://orcid.org/0000-0003-2649-3002
Mamdouh M El-ShishtawyDepartment of Biochemistry, Faculty of Pharmacy, Mansoura University, P.O. Box, Mansoura, 35516, Egypt. mshisht@mans.edu.eg.ORCID http://orcid.org/0000-0002-7888-354X
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to investigate the hepatoprotective effect of sesamol (SML), a nutritional phenolic compound obtained from sesame seeds, in liver fibrosis induced by thioacetamide (TAA) in rats and to explore the underlying mechanisms. Thirty-two male Sprague-Dawley rats were equally divided into four groups: control, TAA, TAA + SML 50 mg/kg, and TAA + SML 100 mg/kg groups. Liver functions and hepatic contents of glutathione (GSH) and malondialdehyde (MDA) were measured colorimetrically. Gene expressions of lysophosphatidic acid receptor (LPAR)-1 and -3, connective tissue growth factor (CTGF), transforming growth factor (TGF)-β1, small mothers against decapentaplegic (Smad)-3 and -7, α-smooth muscle actin (α-SMA), and cytokeratin 19 (CK19) were analyzed by qRT-PCR. Moreover, phosphorylated Smad3 (pSmad3) was quantified by ELISA. Additionally, TGF-β1, α-SMA, CK19, and vascular endothelial growth factor (VEGF) protein concentrations were semi-quantitatively analyzed by immunostaining of liver sections. SML treatment markedly improved liver index and liver functions. Moreover, SML protected against liver fibrosis in a dose-dependent manner as indicated by down-regulation of LPAR1, LPAR3, CTGF, TGF-β1/Smad3, and α-SMA expressions and a decrease in pSmad3 level, as well as an up-regulation of Smad7 expression. In addition, SML suppressed ductular reaction hinted by the decrease in CK19 expression. These results reveal the anti-fibrotic effect of SML against liver fibrosis that might be attributed to down-regulation of LPAR1/3 expressions, inhibition of TGF-β1/Smad3 pathway, and ductular reaction.

Indexed as

Receptors, Lysophosphatidic AcidTransforming Growth Factor beta1AnimalsBenzodioxolesLiverLiver CirrhosisMalePhenolsRatsRats, Sprague-DawleySignal TransductionThioacetamideVascular Endothelial Growth Factor ABenzodioxolesPhenolsReceptors, Lysophosphatidic AcidsesamolThioacetamideTransforming Growth Factor beta1Vascular Endothelial Growth Factor ADuctular reactionLiver fibrosisLPARSesamolTGF-β1/Smad3

Identifiers

PMID35648193
PMCPMC9276582
OpenAlexW4281665155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.